Genentech announced it will present new real-world, product and pipeline data from its ophthalmology portfolio at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, taking place May 3-7 in Denver, Colorado.
The presentations underscore the company’s continued focus on preserving vision through innovative therapies, including Vabysmo (faricimab-svoa), Susvimo (ranibizumab injection) and the investigational interleukin-6 (IL-6) inhibitor vamikibart. The data span five major retinal conditions: geographic atrophy (GA), retinal vein occlusion (RVO), uveitic macular edema (UME), diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (AMD).
Among the highlights is new data from the global VOYAGER study (NCT05476926), which evaluated Vabysmo in real-world clinical practice. Results show that after six months of treatment, patients experienced meaningful drying of the retina and improvements in retinal anatomy.
The study leveraged a deep learning algorithm to analyze optical coherence tomography (OCT) images, offering a novel approach to assessing treatment outcomes in routine care settings. Improvements were observed in both patients new to treatment and those who had previously received other anti-VEGF therapies, reinforcing the therapy’s effectiveness across diverse patient populations.
In addition to Vabysmo, Genentech will present data highlighting the breadth of its ophthalmology portfolio. New findings will explore the use of Vabysmo in retinal vein occlusion, further supporting its real-world utility in managing this condition.
Data on Susvimo will demonstrate its ability to provide sustained disease control, reflecting its role as a long-acting treatment option for chronic retinal diseases. Meanwhile, early-stage results for vamikibart, an investigational IL-6 inhibitor, will provide insight into its potential to address retinal inflammation — a key underlying factor in several vision-threatening conditions.
Overview of key presentations featuring Genentech medicines:
|
Topic |
Abstract Title |
Presentation Details |
|
Vabysmo |
Anatomical outcomes of faricimab in patients with diabetic macular edema: 6-month real-world imaging from the VOYAGER study |
Poster #1964 - 0031 |
|
Long-term effectiveness and safety of faricimab in eyes with nAMD: 2-year results from the UK FARWIDE-nAMD study |
Presentation (10 mins) |
|
|
Automated quantification of retinal fluid volume in patients with DME: analysis of faricimab vs aflibercept in YOSEMITE/RHINE |
Presentation (10 mins) 2:00-2:15 PM |
|
|
Anatomical outcomes of faricimab in patients with neovascular age-related macular degeneration: 6-month real-world imaging from the VOYAGER study |
Presentation (10 mins) |
|
|
Reduction in Subretinal Hyperreflective Material Volume With Faricimab vs Aflibercept 2 mg in Treatment-Naïve nAMD: A TENAYA/LUCERNE Post Hoc Analysis |
Presentation (10 mins) |
|
|
One-year outcomes of faricimab patients with DME from a global, prospective observational study: the VOYAGER study |
Presentation (10 mins) |
|
|
One-year outcomes of faricimab treatment in eyes with nAMD from the global, prospective observational VOYAGER study |
Presentation (10 mins) |
|
|
Susvimo |
Patient preference for the PDS vs intravitreal injections: year 2 results from the phase 3 Pagoda trial in patients with diabetic macular edema (DME) |
Poster #1979 - 0046 3:00- 4:45 PM |
|
Retinal fluid, thickness, and leakage in PDS-treated study eyes vs intravitreal injection-treated fellow eyes in bilateral DME in the Pagoda trial |
Poster #1980 - 0047 |
|
|
Model-based pharmacokinetic simulations of the Port Delivery Platform with ranibizumab (PDS) under various real-world clinical scenarios |
Poster #1981 - 0048 3:00- 4:45 PM |
|
|
Interim analysis of the Belvedere nAMD study: summary of PDS treatment in eyes with high injection burden |
Presentation (10 mins) |
|
|
Vamikibart |
Efficacy and safety of vamikibart in patients with diabetic macular edema: first results from the phase 2 ALLUVIUM trial |
Presentation (10 mins) |
|
Efficacy and safety of vamikibart in combination with ranibizumab in patients with DME: first results from the phase 2 BARDENAS trial |
Presentation (10 mins) |
